|
chemotherapy |
19 |
|
cervical cancer |
18 |
|
gestational trophoblastic neoplasia |
17 |
|
human papillomavirus |
12 |
|
ovarian cancer |
12 |
|
choriocarcinoma |
11 |
|
gestational trophoblastic disease |
11 |
|
intravoxel incoherent motion |
11 |
|
cervical screening |
10 |
|
leiomyosarcoma |
10 |
|
magnetic resonance imaging |
9 |
|
female |
8 |
|
humans |
8 |
|
hysterectomy |
8 |
|
cervical intraepithelial neoplasia |
7 |
|
colposcopy |
7 |
|
diagnostic biomarker |
7 |
|
epithelioid |
7 |
|
gestational |
7 |
|
microrna |
7 |
|
ovarian carcinoma |
7 |
|
sensitivity and specificity |
7 |
|
trophoblastic |
7 |
|
tumors |
7 |
|
anti-müllerian hormone |
6 |
|
base sequence |
6 |
|
cell line, tumor |
6 |
|
checkpoint inhibitor |
6 |
|
cin |
6 |
|
co‐testing |
6 |
|
dce-mri |
6 |
|
diffusion-weighted imaging |
6 |
|
dna methylation |
6 |
|
endometrial carcinoma |
6 |
|
endometrial neoplasms - genetics - metabolism |
6 |
|
epigenesis, genetic |
6 |
|
estrogen receptor alpha - genetics - metabolism |
6 |
|
gynaecological cancer |
6 |
|
hpv testing |
6 |
|
hydatidiform mole |
6 |
|
immunotherapy |
6 |
|
ivim |
6 |
|
lymphadenectomy |
6 |
|
malignant ovarian germ cell tumors |
6 |
|
management |
6 |
|
metallothionein - genetics - metabolism |
6 |
|
metallothionein 1e gene |
6 |
|
molar pregnancy |
6 |
|
molecular sequence data |
6 |
|
neoplasms |
6 |
|
ovarian reserve |
6 |
|
perfusion |
6 |
|
prognosis |
6 |
|
promoter hypermethylation |
6 |
|
promoter regions, genetic |
6 |
|
abdominal pregnancy |
5 |
|
aorta |
5 |
|
cancer survivorship |
5 |
|
carcinosarcoma |
5 |
|
chemoradiotherapy |
5 |
|
contrast-enhanced ct |
5 |
|
diffusion magnetic resonance imaging |
5 |
|
ectopic pregnancy |
5 |
|
fear of cancer recurrence |
5 |
|
hemoperitoneum |
5 |
|
interval debulking surgery |
5 |
|
leiomyoma with bizarre nuclei |
5 |
|
lymph node metastasis |
5 |
|
neo-adjuvant chemotherapy |
5 |
|
observer variation |
5 |
|
patient-initiated follow-up |
5 |
|
pet/ct |
5 |
|
phosphohistone-h3 |
5 |
|
smooth muscle tumour of uncertain malignant potential |
5 |
|
standardized uptake value |
5 |
|
supportive care needs |
5 |
|
uterine cervical neoplasms |
5 |
|
uterine sarcoma |
5 |
|
uterus |
5 |
|
autophagy |
4 |
|
cervical smear |
4 |
|
chamoc regimen |
4 |
|
chemoresistance |
4 |
|
clear cell |
4 |
|
compliance |
4 |
|
education |
4 |
|
endometrial cancer |
4 |
|
first trimester |
4 |
|
follow‐up |
4 |
|
general gynaecology |
4 |
|
high-risk gestational trophoblastic disease |
4 |
|
iaspp |
4 |
|
laparoscopic |
4 |
|
laparotomy |
4 |
|
miscarriage |
4 |
|
misoprostol |
4 |
|
ovarian clear cell carcinoma |
4 |
|
placental site |
4 |
|
placental-site tro phoblastic tumor |
4 |
|
plk1 |
4 |
|
prediction model |
4 |
|
pregnancy |
4 |
|
primary care |
4 |
|
psychological well-being |
4 |
|
quality of life |
4 |
|
robot-assisted |
4 |
|
screening |
4 |
|
serms |
4 |
|
sublingual |
4 |
|
tamoxifen |
4 |
|
trophoblastic tumor |
4 |
|
uterine leiomyosarcoma |
4 |
|
uterine neoplasms |
4 |
|
venous thromboembolism |
4 |
|
adenocarcinoma |
3 |
|
adolescent |
3 |
|
adult |
3 |
|
aneuploidy |
3 |
|
area under the curve |
3 |
|
arias-stella reactionclear |
3 |
|
ca 125 |
3 |
|
cell carcinoma |
3 |
|
cervical carcinoma |
3 |
|
diffusion kurtosis imaging |
3 |
|
dwi |
3 |
|
entropy |
3 |
|
epithelioid trophoblastc tumour |
3 |
|
estrogen receptors |
3 |
|
figo |
3 |
|
follow-up |
3 |
|
histologic subtypes |
3 |
|
hnf-1β |
3 |
|
karyotyping |
3 |
|
leep |
3 |
|
lletz |
3 |
|
methotrexate |
3 |
|
middle aged |
3 |
|
mole |
3 |
|
napsin a |
3 |
|
ovarian cancer recurrence |
3 |
|
peritoneal carcinomatosis |
3 |
|
physical examination |
3 |
|
placental site trophoblastic tumour |
3 |
|
post lletz complications |
3 |
|
prenatal diagnosis |
3 |
|
rapid aneuploidy diagnosis |
3 |
|
retrospective studies |
3 |
|
squamous cell carcinoma |
3 |
|
thalassaemia |
3 |
|
thalassemia - diagnosis - genetics |
3 |
|
adenocarcinoma in situ |
2 |
|
adenosarcoma |
2 |
|
antineoplastic agents - adverse effects - therapeutic use |
2 |
|
atypical leiomyoma |
2 |
|
cancers |
2 |
|
cellular leiomyoma |
2 |
|
cervical |
2 |
|
complications |
2 |
|
cotelydonoid dissecting leiomyoma |
2 |
|
diastole |
2 |
|
dissecting leiomyoma |
2 |
|
dna - methylation. |
2 |
|
endometrial stromal sarcoma |
2 |
|
endometrium - cancer - genetic aspects. |
2 |
|
epithelioid leiomyoma |
2 |
|
fertility preservation |
2 |
|
fetal growth retardation - physiopathology |
2 |
|
gestational age |
2 |
|
gestational trophoblastic disease - complications - psychology - therapy |
2 |
|
gestational trophoblastic meoplasia |
2 |
|
gynaecological cancers |
2 |
|
hpv |
2 |
|
leiomyoma |
2 |
|
medical sciences |
2 |
|
middle cerebral artery - embryology - physiopathology - ultrasonography |
2 |
|
mitotically active leiomyoma |
2 |
|
myxoid leiomyoma |
2 |
|
neoplasm recurrence, local - therapy |
2 |
|
obstetrics and gynecology medical sciences |
2 |
|
organ sparing treatments |
2 |
|
ovarian |
2 |
|
ovaries - cancer |
2 |
|
pediatrics |
2 |
|
peutz jeghers syndrome |
2 |
|
protein kinases |
2 |
|
sil |
2 |
|
squamous intraepithelial lesion |
2 |
|
staging |
2 |
|
stump |
2 |
|
ultrasonography, doppler, pulsed |
2 |
|
undifferentiated endometrial sarcoma |
2 |
|
uterine |
2 |
|
uterine cervix |
2 |
|
uterine smooth muscle tumor of uncertain malignant potential |
2 |
|
vagina |
2 |
|
vaginal squamous intraepithelial neoplasia |
2 |
|
vain |
2 |
|
young women |
2 |
|
aofog opinion |
1 |
|
cancer of the cervix |
1 |
|
chinese |
1 |
|
chronic hepatitis b infection |
1 |
|
covid-19 |
1 |
|
endometrial neoplasms |
1 |
|
gestational diabetes mellitus |
1 |
|
gynecological cancer |
1 |
|
hbv infection |
1 |
|
hpv infection and cin |
1 |
|
operative |
1 |
|
pregnancy outcomes |
1 |
|
risk factor |
1 |
|
sentinel lymph node |
1 |
|
surgical oncology |
1 |
|
surgical procedures |
1 |
